Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:MNOV

MediciNova Q3 2026 Earnings Date & Estimates

MediciNova logo
$1.36 -0.04 (-2.86%)
Closing price 10/20/2026 04:00 PM Eastern
Extended Trading
$1.36 +0.00 (+0.07%)
As of 10/20/2026 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MediciNova is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from MediciNova in Q3 2026

MediciNova is expected to post earnings of -$0.06 per share on revenue of $0.05 million. In the same quarter a year earlier MediciNova reported -$0.06 per share on revenue of $0.12 million. MediciNova last reported on August 13, 2026, posting -$0.05 per share and beating the -$0.0633 consensus estimate. MediciNova has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.06
Expected Revenue
$0.05 million
Prior-Year EPS
-$0.06
Prior-Year Revenue
$0.12 million
Expected Revenue Growth
-59.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.05 (Beat by +$0.0133)
Last Quarter Revenue
$0.46 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

MediciNova Q3 2026 Earnings FAQ

MediciNova (NASDAQ:MNOV) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

MediciNova's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect MediciNova to post earnings of -$0.06 per share for Q3 2026.

The consensus revenue estimate for MediciNova is $0.05 million for Q3 2026.

MediciNova Earnings Headlines

Phibro Animal Health (NASDAQ:PAHC) and MediciNova (NASDAQ:MNOV) Head to Head Survey
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109475
MediciNova to Participate in the Maxim Growth Summit
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375268/7767/en/medicinova-to-participate-in-the-maxim-growth-summit.html
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
October 21 at 1:00 AM  |  Porter & Company (Ad)
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/medicinova-stock-tumbles-mixed-phase-132051602.html
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/medicinova-shares-fall-phase-2-135826324.html
MediciNova Reports Phase 2 MN-001 Data In T2DM-Associated NAFLD; Stock Plunges In Premarket
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694277/medicinova-reports-phase-2-mn-001-data-in-t2dm-associated-nafld-stock-plunges-in-premarket.aspx
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory, and other serious medical conditions. The company is headquartered in La Jolla, California, and its programs are primarily directed toward conditions with significant unmet treatment needs.

Its lead investigational product, MN-166 (ibudilast), is being studied in several neurological indications, including amyotrophic lateral sclerosis, progressive multiple sclerosis, and substance use disorders. MediciNova is also developing MN-001 (tipelukast), an investigational therapy being evaluated for fibrotic and inflammatory diseases, including nonalcoholic steatohepatitis and pulmonary conditions. These products have not received broad regulatory approval for the indications under investigation.

MediciNova was founded in 2000 and has pursued a strategy of licensing and developing drug candidates for international markets, with research and clinical activities involving the United States and Japan. The company is led by Yuichi Iwaki, M.D., Ph.D., who serves as president and chief executive officer.

View MediciNova Profile
Earnings Tools